Tirzepatide 60mg

TR is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Its twin-incretin pharmacology has generated significant research interest in metabolic disease, covering insulin secretion, glucagon suppression, gastric emptying, and adipose tissue biology.

Presentation

60 mg Pen

Purity

99.59%

Sold strictly for in-vitro laboratory research. Not for human or veterinary consumption.